Clinical Trial Update: HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Adebrelimab in combination with Bevacizumab and hepatic artery infusion of FOLFOX for advanced unresectable hepatocellular carcinoma is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)
• Bevacizumab (bevacizumab)
• FOLFOX regimen (hepatic artery infusion) (FOLFOX)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING